Cipher Pharmaceuticals (CPH) Set to Announce Quarterly Earnings on Wednesday

Cipher Pharmaceuticals (TSE:CPH) (NASDAQ:CPHR) is scheduled to announce its earnings results before the market opens on Wednesday, November 7th. Analysts expect the company to announce earnings of C$0.12 per share for the quarter.

Cipher Pharmaceuticals (TSE:CPH) (NASDAQ:CPHR) last announced its earnings results on Friday, August 10th. The company reported C$0.09 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of C$0.14 by C($0.05). Cipher Pharmaceuticals had a net margin of 32.44% and a return on equity of 75.47%. The firm had revenue of C$8.98 million during the quarter, compared to analysts’ expectations of C$8.54 million.

Shares of CPH opened at C$2.72 on Wednesday. Cipher Pharmaceuticals has a twelve month low of C$2.63 and a twelve month high of C$5.28.

Separately, TD Securities raised shares of Cipher Pharmaceuticals from a “hold” rating to a “buy” rating and set a C$4.25 target price on the stock in a research note on Monday, August 13th.

About Cipher Pharmaceuticals

Cipher Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. The company offers EPURIS (CIP-ISOTRETINOIN), a formulation of the active ingredient isotretinoin for use in the treatment of severe acne; LIPOFEN (CIP-FENOFIBRATE), a formulation of the active ingredient fenofibrate used for the treatment of hyperlipidemia, a cholesterol disorder; CONZIP/DURELA (CIP-TRAMADOL ER), a formulation of the active ingredient tramadol for the management of moderate to moderately severe pain; and Absorica, an oral retinoid indicated for the treatment of severe recalcitrant nodular acne in patients.

Featured Article: Treasury Bonds

Earnings History for Cipher Pharmaceuticals (TSE:CPH)

Receive News & Ratings for Cipher Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cipher Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply